JP2015509948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509948A5 JP2015509948A5 JP2014558901A JP2014558901A JP2015509948A5 JP 2015509948 A5 JP2015509948 A5 JP 2015509948A5 JP 2014558901 A JP2014558901 A JP 2014558901A JP 2014558901 A JP2014558901 A JP 2014558901A JP 2015509948 A5 JP2015509948 A5 JP 2015509948A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 39
- 101000864751 Homo sapiens Seizure protein 6 homolog Proteins 0.000 claims description 30
- 102100030057 Seizure protein 6 homolog Human genes 0.000 claims description 30
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 239000000611 antibody drug conjugate Substances 0.000 claims description 12
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000002254 cytotoxic agent Substances 0.000 claims description 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical group C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 4
- 101100477420 Homo sapiens SEZ6 gene Proteins 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- -1 maytansinoid Chemical compound 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603203P | 2012-02-24 | 2012-02-24 | |
| US61/603,203 | 2012-02-24 | ||
| PCT/US2013/027476 WO2013126810A1 (en) | 2012-02-24 | 2013-02-22 | Anti sez6 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018052506A Division JP2018127469A (ja) | 2012-02-24 | 2018-03-20 | 抗ｓｅｚ６抗体及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509948A JP2015509948A (ja) | 2015-04-02 |
| JP2015509948A5 true JP2015509948A5 (OSRAM) | 2016-04-14 |
| JP6401060B2 JP6401060B2 (ja) | 2018-10-03 |
Family
ID=47790548
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558901A Expired - Fee Related JP6401060B2 (ja) | 2012-02-24 | 2013-02-22 | 抗ｓｅｚ６抗体及び使用方法 |
| JP2018052506A Pending JP2018127469A (ja) | 2012-02-24 | 2018-03-20 | 抗ｓｅｚ６抗体及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018052506A Pending JP2018127469A (ja) | 2012-02-24 | 2018-03-20 | 抗ｓｅｚ６抗体及び使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9676850B2 (OSRAM) |
| EP (2) | EP3539985A1 (OSRAM) |
| JP (2) | JP6401060B2 (OSRAM) |
| KR (1) | KR102099073B1 (OSRAM) |
| CN (2) | CN104334580B (OSRAM) |
| AU (3) | AU2013203506B2 (OSRAM) |
| CA (1) | CA2865415C (OSRAM) |
| CL (2) | CL2014002237A1 (OSRAM) |
| CO (1) | CO7151485A2 (OSRAM) |
| ES (1) | ES2741936T3 (OSRAM) |
| IL (1) | IL234208B (OSRAM) |
| MX (2) | MX373141B (OSRAM) |
| MY (1) | MY178120A (OSRAM) |
| NZ (1) | NZ631197A (OSRAM) |
| PE (1) | PE20150091A1 (OSRAM) |
| PH (2) | PH12020500604A1 (OSRAM) |
| RU (1) | RU2691698C2 (OSRAM) |
| SG (2) | SG10201801444WA (OSRAM) |
| WO (1) | WO2013126810A1 (OSRAM) |
| ZA (1) | ZA201406967B (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2741936T3 (es) * | 2012-02-24 | 2020-02-12 | Abbvie Stemcentrx Llc | Anticuerpos anti-SEZ6 y procedimientos de uso |
| US11531028B2 (en) * | 2013-05-10 | 2022-12-20 | Nordic Bioscience A/S | Collagen type X alpha-1 assay |
| EP3338793A1 (en) * | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
| PE20160674A1 (es) * | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones |
| EP3065780A1 (en) * | 2013-11-04 | 2016-09-14 | Pfizer Inc. | Anti-efna4 antibody-drug conjugates |
| WO2015084262A2 (en) * | 2013-12-03 | 2015-06-11 | Agency For Science, Technology And Research | Cytotoxic antibody |
| JP6818268B2 (ja) * | 2014-01-29 | 2021-01-20 | Ｋｍバイオロジクス株式会社 | 抗トランスサイレチンヒト化抗体 |
| EP3981874A1 (en) * | 2014-01-29 | 2022-04-13 | KM Biologics Co., Ltd. | Anti-transthyretin human antibody |
| EA201691683A1 (ru) | 2014-02-21 | 2017-04-28 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме |
| WO2015200073A1 (en) * | 2014-06-23 | 2015-12-30 | Bionomics, Inc. | Antibodies that bind lgr4 |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| US9688750B2 (en) | 2014-10-07 | 2017-06-27 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Anti-nodal antibodies and methods of using same |
| EA201890530A1 (ru) * | 2015-08-20 | 2018-09-28 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения |
| US11294038B2 (en) | 2015-10-06 | 2022-04-05 | Pioneer Corporation | Light control device, light control method and program |
| US20180346571A1 (en) * | 2015-11-17 | 2018-12-06 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| WO2018071718A1 (en) | 2016-10-14 | 2018-04-19 | Nima Labs, Inc. | Anti-gliadin antibodies |
| JP2020502042A (ja) * | 2016-10-19 | 2020-01-23 | ノヴェロジックス・バイオテクノロジー，インコーポレーテッド | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| EP3559043A4 (en) * | 2016-12-23 | 2020-08-05 | Bluefin Biomedicine, Inc. | ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES |
| EP3424527A1 (de) | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Diagnostisches verfahren |
| US11795230B2 (en) | 2018-04-13 | 2023-10-24 | Dingfu Biotarget Co., Ltd. | Anti-CD27 antibodies and use thereof |
| ES2867148T3 (es) * | 2018-05-30 | 2021-10-20 | Abbvie Stemcentrx Llc | Conjugados farmacológicos de anticuerpo anti-SEZ6 y métodos de uso |
| US12091453B2 (en) * | 2018-07-11 | 2024-09-17 | Hedgehog, Inc. | Epitope specific to SMO protein, antibody recognizing same, and composition comprising same |
| US12220604B2 (en) | 2018-07-31 | 2025-02-11 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of an antibody-drug conjugate |
| CA3105527A1 (en) * | 2018-08-24 | 2020-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| CN114106176B (zh) * | 2020-09-01 | 2024-04-09 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
| WO2022051223A1 (en) * | 2020-09-02 | 2022-03-10 | The Feinstein Institutes For Medical Research | Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19 |
| US20240269304A1 (en) | 2020-11-24 | 2024-08-15 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN114790241B (zh) * | 2021-01-26 | 2024-12-13 | 北京免疫方舟医药科技有限公司 | 抗tigit抗体及其应用 |
| CN113307875B (zh) * | 2021-06-10 | 2022-09-02 | 福州迈新生物技术开发有限公司 | 抗TCRβF1蛋白单克隆抗体及其细胞株、制备方法和应用 |
| WO2023019174A2 (en) * | 2021-08-11 | 2023-02-16 | Apollos Diagnostics, Llc | Antibodies to sars-cov-2 |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| KR20250011947A (ko) | 2022-05-20 | 2025-01-22 | 노파르티스 아게 | 항체 약물 콘쥬게이트 |
| CN115975036B (zh) * | 2022-08-18 | 2023-06-09 | 北京诺赛国际医学研究院 | 包含干细胞的药物组合物及其治疗癌症的用途 |
| AU2024270504A1 (en) * | 2023-05-08 | 2025-11-27 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Antibody or antigen-binding fragment thereof, antibody-drug conjugate, and use thereof |
| CN117736331B (zh) * | 2024-02-04 | 2024-05-07 | 南昌大学第一附属医院 | 一种特异性结合psma胞外段的单克隆抗体及其应用 |
| WO2025167503A1 (en) * | 2024-02-05 | 2025-08-14 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-sez6/b7h3 antibodies and uses thereof |
| CN120365421B (zh) * | 2025-04-24 | 2025-11-04 | 成都古格尔生物技术有限公司 | 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| AU643109B2 (en) | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| AU3382595A (en) | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| DK1193270T3 (da) | 1998-08-27 | 2003-09-15 | Spirogen Ltd | Pyrrolobenzodiazepiner |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| AU2001256977A1 (en) * | 2000-04-28 | 2001-11-12 | Eli Lilly And Company | Human sez6 nucleic acids and polypeptides |
| US7608704B2 (en) | 2000-11-08 | 2009-10-27 | Incyte Corporation | Secreted proteins |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| US20030211991A1 (en) | 2001-04-17 | 2003-11-13 | Su Eric Wen | Human sez6 nucleic acids and polypeptides |
| CN1343774A (zh) | 2001-05-28 | 2002-04-10 | 复旦大学 | 一种癫痫相关蛋白编码序列,其编码的多肽、制法及用途 |
| CA2478239A1 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| CA2525899C (en) | 2003-05-09 | 2016-03-08 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CA2558195C (en) | 2004-03-01 | 2012-11-06 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
| MX2008015492A (es) | 2006-06-06 | 2009-02-12 | Univ Tennessee Res Foundation | Composiciones enriquecidas en celulas madre neoplasicas y metodos que las contienen. |
| DK2044120T3 (da) | 2006-06-07 | 2019-04-15 | Bioalliance Cv | Antistoffer, der genkender en kulhydratholdig epitop på cd-43 og cea eksprimeret på cancerceller, og fremgangsmåder til anvendelse deraf |
| PT3207941T (pt) | 2006-09-07 | 2020-04-02 | Scott & White Memorial Hospital | Métodos e composições baseados em conjugados de toxina diftérica-interleucina-3 |
| CN101855339A (zh) | 2007-01-22 | 2010-10-06 | 雷文生物技术公司 | 人类癌症干细胞 |
| NZ600758A (en) * | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| WO2009012357A2 (en) | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| MX2010007767A (es) | 2008-01-18 | 2010-08-09 | Medimmune Llc | Anticuerpos manipulados con cisteina para conjugacion especifica de sitio. |
| CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| KR20110108390A (ko) | 2009-01-12 | 2011-10-05 | 신텔렉트 인코포레이티드 | 레이저로 매개된 박막 절개 및 세포 군체의 이동 |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| TW201119673A (en) | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| SG10201501803YA (en) * | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| NZ602932A (en) | 2010-04-15 | 2014-08-29 | Seattle Genetics Inc | Targeted pyrrolobenzodiazapine conjugates |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| CN102971329B (zh) | 2010-04-15 | 2016-06-29 | 麦迪穆有限责任公司 | 用于治疗增殖性疾病的吡咯并苯并二氮杂卓 |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2012012801A2 (en) | 2010-07-23 | 2012-01-26 | The Johns Hopkins University | Device for capture, enumeration, and profiling of circulating tumor cells |
| WO2012019060A1 (en) * | 2010-08-05 | 2012-02-09 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| WO2012031280A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US8637642B2 (en) | 2010-09-29 | 2014-01-28 | Seattle Genetics, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
| ES2741936T3 (es) * | 2012-02-24 | 2020-02-12 | Abbvie Stemcentrx Llc | Anticuerpos anti-SEZ6 y procedimientos de uso |
| EP3338793A1 (en) * | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
| PE20160674A1 (es) * | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones |
| US20190209704A1 (en) | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
| MA41645A (fr) * | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
| EP3559043A4 (en) | 2016-12-23 | 2020-08-05 | Bluefin Biomedicine, Inc. | ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES |
-
2013
- 2013-02-22 ES ES13707529T patent/ES2741936T3/es active Active
- 2013-02-22 PH PH1/2020/500604A patent/PH12020500604A1/en unknown
- 2013-02-22 CA CA2865415A patent/CA2865415C/en active Active
- 2013-02-22 RU RU2014138420A patent/RU2691698C2/ru active
- 2013-02-22 PE PE2014001301A patent/PE20150091A1/es active IP Right Grant
- 2013-02-22 CN CN201380010534.6A patent/CN104334580B/zh not_active Expired - Fee Related
- 2013-02-22 JP JP2014558901A patent/JP6401060B2/ja not_active Expired - Fee Related
- 2013-02-22 MY MYPI2014002467A patent/MY178120A/en unknown
- 2013-02-22 EP EP19154773.6A patent/EP3539985A1/en not_active Withdrawn
- 2013-02-22 US US14/380,665 patent/US9676850B2/en active Active
- 2013-02-22 AU AU2013203506A patent/AU2013203506B2/en not_active Ceased
- 2013-02-22 KR KR1020147026846A patent/KR102099073B1/ko not_active Expired - Fee Related
- 2013-02-22 CN CN201810153825.5A patent/CN108383909B/zh not_active Expired - Fee Related
- 2013-02-22 MX MX2014010094A patent/MX373141B/es active IP Right Grant
- 2013-02-22 SG SG10201801444WA patent/SG10201801444WA/en unknown
- 2013-02-22 EP EP13707529.7A patent/EP2817339B1/en active Active
- 2013-02-22 NZ NZ631197A patent/NZ631197A/en not_active IP Right Cessation
- 2013-02-22 WO PCT/US2013/027476 patent/WO2013126810A1/en not_active Ceased
- 2013-02-22 SG SG11201405130UA patent/SG11201405130UA/en unknown
-
2014
- 2014-08-19 IL IL234208A patent/IL234208B/en active IP Right Grant
- 2014-08-21 MX MX2020003713A patent/MX2020003713A/es unknown
- 2014-08-22 CL CL2014002237A patent/CL2014002237A1/es unknown
- 2014-08-26 PH PH12014501914A patent/PH12014501914A1/en unknown
- 2014-09-23 CO CO14210871A patent/CO7151485A2/es unknown
- 2014-09-23 ZA ZA2014/06967A patent/ZA201406967B/en unknown
-
2016
- 2016-09-07 AU AU2016225828A patent/AU2016225828B2/en not_active Ceased
-
2017
- 2017-06-05 US US15/614,548 patent/US10533051B2/en not_active Expired - Fee Related
- 2017-11-08 CL CL2017002823A patent/CL2017002823A1/es unknown
-
2018
- 2018-03-20 JP JP2018052506A patent/JP2018127469A/ja active Pending
- 2018-08-31 AU AU2018223053A patent/AU2018223053B2/en not_active Expired - Fee Related
-
2019
- 2019-12-12 US US16/712,324 patent/US20200181256A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509948A5 (OSRAM) | ||
| JP2015509947A5 (OSRAM) | ||
| JP2018127469A5 (OSRAM) | ||
| ES2566602T3 (es) | Anticuerpos anti-ErbB3 | |
| JP2016538318A5 (OSRAM) | ||
| JP2016510002A5 (OSRAM) | ||
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| JP2016536020A5 (OSRAM) | ||
| HRP20191169T1 (hr) | Konjugati antidll3-protutijelo-pbd i njihove uporabe | |
| JP2017500028A5 (OSRAM) | ||
| JP2017518040A5 (OSRAM) | ||
| JP2016512551A5 (OSRAM) | ||
| JP2011046732A5 (OSRAM) | ||
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2017512765A5 (OSRAM) | ||
| RU2019118359A (ru) | Антитело к cd73 человека | |
| JP2017535246A5 (OSRAM) | ||
| JP2019532056A5 (OSRAM) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2010520290A5 (OSRAM) | ||
| JP2015503909A5 (OSRAM) | ||
| IL278574B1 (en) | Compounds acting on glycans and methods of using them | |
| RU2016145277A (ru) | Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака | |
| JP2016505546A5 (OSRAM) | ||
| JP2014502955A5 (OSRAM) |